Nikhil Narang, MD

What is the burden of VAD related AE’s in pts w/ HM3 VAD w/ and w/out temp RVAD? At 1-Yr: ⬆️ mortality ⬆️ risk of dialysis ⬆️ stroke (propensity matched) 🟰 risk GIB, infection, VT Our large Advocate experience now in @ESCHeartFailure 📎 onlinelibrary.wiley.com/doi/10.1002/eh…

Is iron deficiency anemia associated w/ exercise capacity in patients with LVADs? 🏃 Check out a quick take by @dranulala on a new JCF Brief Report exploring the link between iron deficiency anemia and pVO₂ on CPET. Dive deeper into the study here: bit.ly/4l0XXJe

We know AI-ECG and AI-Echo can detect transthyretin amyloid cardiomyopathy (ATTR-CM), but: – How early can they pick up the phenotype? – Can we track its progression with digital biomarkers? Find out in our @cards_lab study in @ehj_ed Thread below 🧵👇 w/ @rohan_khera…

So proud to be a part of two great teams @UChicagoCardio @EndeavorHlth to help grow the reach of HF therapies for our patients in both northern + southern Chicago @uchicagohvc @benchungmd @MarkBelkinMD @manreetkanwar @JonGrinsteinMD @LeoGozdeckiDO @GeneKimMD @KanelidisMD

The Legendary Rob Mentz from @DukeCardiology and co-editor of @JCardFail took the stage at the #CharlestonHFpEF Conference to tackle diuretics & decongestion—leading us through TRANSFORM like only he can. A fluid talk, in every sense. 💧 “How much diuretic do I give? Answer:…

Dr. Muthu Vaduganathan from @harvardmed brought MRAs back into the spotlight at the #CharlestonHFpEF Conference, highlighting the FINEARTS trial—because when it comes to HFpEF, mineralocorticoid blockade is looking like a fine art indeed. More data coming! 🎨🫀 #HFpEF…

Dr. Nosheen Reza just gave a TED-style masterclass on HCM—aka the OG HFpEF—at #CharlestonHFpEF. Crystal clear, high impact, and delivered like a boss. 👏🫀 #HCMQueen @noshreza @heartsuccessMD

In this analysis from @hfcollaboratory, we looked at the collection of SDOH in HF clinical trials and proposed a SDOH lean CRF for use moving forward. Full paper now in @JACCJournals #JACCHF ➡️ sciencedirect.com/science/articl… 🧵to follow

Call for Papers: Focus Issue: Infiltrative & Inflammatory Cardiomyopathies Guest Editors Drs. Nisha Gilotra, Mat Maurer, and Emer Joyce will oversee this issue, publishing Winter 2026. Paper Categories & Topic Areas: bit.ly/46gZVRq 📆 Deadline: Oct 6, 2025

This week, we raised Dr. Roberto Lang’s lead to the #UChicagoCathLab rafters in tribute to our dear friend & the luminary we @UChicagoMed had the privilege to learn so much from. Thank you for everything Roberto. You will be missed. #CardioTwitter

Thank you to our phenomenal #UChicagoCathLab crew for continuing to deliver outstanding care as our #STEMI volume increased 2X increase 2025! On behalf of all the @UChicagoCardio & @uchicagohvc IC operators, it’s truly a pleasure and a privilege to have you on our team. 🙏

Save the Date! 📅 The 2nd Annual Chicago Hemodynamic Forum will take place on Friday, November 14th, at UChicago 🫀 Registration is open NOW! uchicagohemodynamics.com #Cardiology #Cardiotwitter #HeartFailure #hearthealth #heartdisease

Clinical trial #endpoints in pragmatic heart failure #RCTs Insightful review on selection, classification, and data capture of pragmatic trial endpoints led by @vkittipibul #AdamDevore @DCRINews 🔗 onlinelibrary.wiley.com/doi/epdf/10.10… #TrialDesign #ResearchMethods #RCTs

Proud to see our work on value of #WhyCMR in ATTR-CA with grade 0-1 Tc-PyP in @JACCJournals imaging. 💡 12% of biopsy-proven ATTR-CA have grade 0-1 PyP. Further testing needed if high suspicion. 💡ECV accurately identified ATTR-CA with grade 0-1 Tc-PyP 🔗sciencedirect.com/science/articl…

Happy to share CSWG's deep dive into IABP use in CS noting differential outcomes with IABP by etiology (MI vs HF) and suggesting acute hemodynamic effects of IABP may differ between these as well @rachkataria @ShashankSinhaMD @JHMontfort10 @manreetkanwar sciencedirect.com/science/articl…

Progress .... but still long way to go with implementing #SGLT2i for #HF in 🇺🇸 🚨 <1 in 6 w/ HF prescribed #SGLT2i 🚨 Adjusted for pt and practice characteristics, odds of SGLT2i varies by >4 fold depending on clinic pt goes to @JAMACardio @DCRINews jamanetwork.com/journals/jamac…

🚨 Finerenone Approved by US FDA in HF based on #FINEARTSHF Finerenone (Kerendia) is a non-steroidal MRA indicated to reduce the risk of CV death, hospitalization for HF, & urgent HF visits in adult patients with HF with LVEF>= 40% bayer.com/media/en-us/us…

Excited to share our latest publication in #JACCCaseReports on how home #hospice is an underutilized option for patients with #LVAD in end-of-life. This was a collaborative work with our phenomenal #palliativecare team @EVMSMedicine! @JACCJournals ➡️Link: kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F%2…

Gp 1 PH with high HFpEF probability have less clinical improvement with traditional PH therapy, compared to gp 1 PH + low HFpEF prob. Do we need more intensive PH therapy, sotatercept or HFpEF therapies for these pts? Many unknowns that need RCTs. publications.ersnet.org/content/erj/ea…

This AI screening model used only an apical 4ch echo videoclip & effectively differentiated cardiac amyloidosis from other causes of ⬆️ wall thickness

Just published in European Heart Journal — a global milestone in AI-powered cardiac care. @UChicagoMed’s Drs. Jeremy Slivnick and Roberto Lang (in memoriam) helped lead a multi-center, international study — in collaboration with Dr. Patricia Pellikka (Mayo Clinic) and the…